Voyager Therapeutics

Update in progress

VYGR (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Voyager Therapeutics is a biotechnology company focused on human genetics to treat neurological diseases. Its pipeline includes VY1706, a tau-silencing gene therapy, and VY7523, an anti-tau antibody for Alzheimer’s disease. It also advances Huntington’s disease programs. Voyager offers TRACER, an AAV capsid discovery platform, and ALPL-VYGR-NeuroShuttle for another CNS target, plus selective small molecules for ALS and FTD-TDP-43. Founded 2013, Lexington, MA.

Company score

Sentiment: -0.20; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.19; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.02; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.13; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive